Circa 2019 o,.o.

For more than 50 years, cardiac surgeons and biomedical engineers at the Texas Heart Institute (THI) have been questing for an artificial heart that can fully replace natural ones, which are in terribly short supply for transplant. They’ve seen their share of metal and plastic contraptions that used a variety of pumping mechanisms, but none of these machines could match the astounding performance of the human heart.

In April 2019, the possible culmination of that long quest was inside a shaggy brown cow, which stood peacefully chewing its cud at a THI research facility in Houston. The animal was part of a 90-day trial in which it lived its life powered by an implanted artificial heart made by our company, Bivacor. Throughout the trial, the calf stayed healthy and energetic, and gained weight at a normal rate. It even jogged on a treadmill for 30-minute stretches.

Continue reading “This Maglev Heart Could Keep Cardiac Patients Alive” »

Circa 2019

The evolution of micro and nanofabrication approaches significantly spurred the advancements of cardiac tissue engineering over the last decades. Engineering in the micro and nanoscale allows for the rebuilding of heart tissues using cardiomyocytes. The breakthrough of human induced pluripotent stem cells expanded this field rendering the development of human tissues from adult cells possible, thus avoiding the ethical issues of the usage of embryonic stem cells but also creating patient-specific human engineered tissues. In the case of the heart, the combination of cardiomyocytes derived from human induced pluripotent stem cells and micro/nano engineering devices gave rise to new therapeutic approaches of cardiac diseases. In this review, we survey the micro and nanofabrication methods used for cardiac tissue engineering, ranging from clean room-based patterning (such as photolithography and plasma etching) to electrospinning and additive manufacturing. Subsequently, we report on the main approaches of microfluidics for cardiac culture systems, the so-called “Heart on a Chip”, and we assess their efficacy for future development of cardiac disease modeling and drug screening platforms.

Circa 2020

The FRESH technique of 3D bioprinting was invented in Feinberg’s lab to fill an unfilled demand for 3D printed soft polymers, which lack the rigidity to stand unsupported as in a normal print. FRESH 3D printing uses a needle to inject bioink into a bath of soft hydrogel, which supports the object as it prints. Once finished, a simple application of heat causes the hydrogel to melt away, leaving only the 3D bioprinted object.

Continue reading “3D bioprinted heart provides new tool for surgeons” »

OSAKA – An Osaka University team said it has carried out the world’s first transplant of cardiac muscle cells created from iPS cells in a physician-initiated clinical trial.

In the clinical project to verify the safety and efficacy of the therapy using induced pluripotent stem cells, Yoshiki Sawa, a professor in the university’s cardiovascular surgery unit, and colleagues aim to transplant heart muscle cell sheets over the course of three years into 10 patients suffering from serious heart malfunction caused by ischemic cardiomyopathy.

Summary: Neuroinflammation may be a key player in the pathological brain changes produced as a result of chronic opioid use. Microglia is likely responsible for the majority of the changes.

Source: boston university school of medicine.

Prevalence rates of opioid use disorder (OUD) have increased dramatically, accompanied by a surge of overdose deaths–nearly 50000 in the U.S. in 2019. While opioid dependence has been extensively studied in preclinical models, an understanding of the biological alterations that occur in the brains of people who chronically use opioids and who are diagnosed with OUD remains limited.

Close to a month on, internet-facing servers remain vulnerable to attack.

By employing a neural network, the company says its numbers will be more accurate—and allow it to offer to buy more homes.

Stem cell biologist Hugo Vankelecom (KU Leuven) and his colleagues have discovered that the pituitary gland in mice ages as the result of an age-related form of chronic inflammation. It may be possible to slow down this process or even partially repair it. The researchers have published their findings in PNAS.

The pituitary gland is a small, globular gland located underneath the brain that plays a major role in the hormonal system, explains Professor Hugo Vankelecom from the Department of Development and Regeneration at KU Leuven. “My research group discovered that the pituitary gland ages as a result of a form of chronic inflammation that affects tissue and even the organism as a whole. This natural process usually goes unnoticed and is referred to as ‘inflammaging’—a contraction of inflammation and aging. Inflammaging has previously been linked to the aging of other organs.” Due to the central role played by the pituitary, its aging may contribute to the reduction of hormonal processes and hormone levels in our body—as is the case with menopause, for instance.

The study also provides significant insight into the stem cells in the aging pituitary gland. In 2012, Vankelecom and his colleagues showed that a prompt reaction of these stem cells to injury in the gland leads to repair of the tissue, even in adult animals. “As a result of this new study, we now know that stem cells in the pituitary do not lose this regenerative capacity when the organism ages. In fact, the stem cells are only unable to do their job because, over time, the pituitary becomes an ‘inflammatory environment’ as a result of the chronic inflammation. But as soon as the stem cells are taken out of this environment, they show the same properties as stem cells from a young pituitary.”

In a minute and 27 seconds we get the what from an eye regeneration for mice, to monkey trials to start later this year, to human trials by 2023, and full body in a decade.

David Sinclair—a world-leading biologist, Harvard Medical School Professor, and author of The New York Times best-selling book @Lifespan.

Continue reading “When can we begin to apply age reversal gene therapies to humans? Harvards David Sinclair explains” »